{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-25-000025","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.859303+00:00","generated_at":"2026-05-22T07:16:20.864846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74","bullets":["Net revenues $170.5M, down from $171.8M in Q1 2024.","GAAP net income $25.3M ($0.51 diluted EPS) vs $43.2M ($0.81) last year.","Adjusted non-GAAP net income $36.9M ($0.74 EPS) vs $55.3M ($1.04) prior year.","CEO cites BAQSIMI and Primatene MIST growth; FDA accepted insulin biosimilar AMP-004 application.","Company managing resources for efficient operations amid revenue decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-25-000025","json":"https://secwatch.observer/filing/0001297184-25-000025.json","markdown":"https://secwatch.observer/filing/0001297184-25-000025.md","text":"https://secwatch.observer/filing/0001297184-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/0001297184-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000025/amph-20250507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:16:20.864846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}